It was known that lung adenocarcinoma can be transformed into neuroendocrine carcinoma under epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment, leading to resistance in EGFR-mutated non-small-cell lung cancers [46,47]. Here, EGFR is linked to non-small cell lung carcinoma.